Role of Epigenomics in Ovarian and Endometrial Cancers
Authors:
- 2 June 2010
- journal article
- review article
- Published by Taylor & Francis in Epigenomics
- Vol. 2 (3) , 419-447
Abstract
Ovarian cancer is the most lethal gynecologic malignancy and while constituting only 3% of all female cancers, it causes 14,600 deaths in the USA annually. Endometrial cancer, the most diagnosed and second-most fatal gynecologic cancer, afflicts over 40,000 US women annually, causing an estimated 7780 deaths in 2009. In both advanced ovarian and endometrial carcinomas, the majority of initially therapy-responsive tumors eventually evolve to a fully drug-resistant phenotype. In addition to genetic mutations, epigenetic anomalies are frequent in both gynecologic malignancies, including aberrant DNA methylation, atypical histone modifications and dysregulated expression of distinct microRNAs, resulting in altered gene-expression patterns favoring cell survival. In this article, we summarize the most recent hypotheses regarding the role of epigenetics in ovarian and endometrial cancers, including a possible role in tumor 'stemness' and also evaluate the possible therapeutic benefits of reversal of these oncogenic chromatin aberrations.Keywords
Funding Information
- National Cancer Institute awards (CA085289, CA113001, CA133877)
- Walther Cancer Foundation
- Eisai
This publication has 257 references indexed in Scilit:
- Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem CellsCell, 2009
- Identification of microRNA‐181 by genome‐wide screening as a critical player in EpCAM–positive hepatic cancer stem cells†Hepatology, 2009
- Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum‐induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancerInternational Journal of Cancer, 2009
- Downregulation of connective tissue growth factor by three‐dimensional matrix enhances ovarian carcinoma cell invasionInternational Journal of Cancer, 2009
- Identification of miR‐21 targets in breast cancer cells using a quantitative proteomic approachProteomics, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- miR-296 Regulates Growth Factor Receptor Overexpression in Angiogenic Endothelial CellsCancer Cell, 2008
- Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cellsBiochemical Pharmacology, 2008
- Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cellsGynecologic Oncology, 2007
- The Epigenomics of CancerCell, 2007